Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Nature of Business and Significant Accounting Policies (Long-lived assets) (Details) (USD $)	3 Months Ended	12 Months Ended				3 Months Ended
	Dec. 31, 2014 sqft	Dec. 31, 2014 sqft	Dec. 31, 2013	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013	Mar. 31, 2012 sqft	Sep. 30, 2011 sqft
Impaired Long-Lived Assets Held and Used [Line Items]
Gain (Loss) on Disposition of Business		$ 1,200,000us-gaap_GainLossOnSaleOfBusiness
Other Asset Impairment Charges		700,000us-gaap_OtherAssetImpairmentCharges
Asset Impairment Charges	600,000us-gaap_AssetImpairmentCharges	2,086,000us-gaap_AssetImpairmentCharges	0us-gaap_AssetImpairmentCharges
Net Rentable Area	9,000us-gaap_NetRentableArea	9,000us-gaap_NetRentableArea					6,700us-gaap_NetRentableArea	47,000us-gaap_NetRentableArea
Segment, Discontinued Operations [Member]
Impaired Long-Lived Assets Held and Used [Line Items]
Asset Impairment Charges				600,000	700,000
Marketing Services [Member]
Impaired Long-Lived Assets Held and Used [Line Items]
Asset Impairment Charges			$ 600,000			$ 100,000